BiPar Sciences
BiPar Sciences accelerates clinical program with new financing
Published in Oncology Business Week, July 16th, 2006
The company plans to use the funding to accelerate and expand the clinical program for its lead compound, BSI-201, and move two additional compounds toward clinical development.
"The additional funding will allow us to expand clinical development ahead of plan on our promising lead compound, BSI-201, while continuing to push our second clinical candidate toward its investigational new drug (IND) application with the Food and Drug Administration," said...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- ArQule
ArQule announces promising data from phase I trials with ARQ 501, chemotherapeutic agents - ChondroGene
ChondroGene presents data on blood-based detection of colon, prostate cancer - Covance Research Products
Covance reports Signet release of new monoclonal antibodies, acquisition of company's assets - Decision Resources
Physician available through market research company to discuss first cervical cancer vaccine - East China University of Science & Technology, People's Republic of China
HIV-TAT-survivin (T34A) mutant has been constructed and purified - Emory University
Recent studies from the United States and Japan add new data to lung cancer research - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
